Hong-Rong Fei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hong-Rong Fei has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Feng-Ze Wang
Center Laboratory, The Second Affiliated Hospital of Shandong First Medical University, Taian, 271000, China
3 shared publications Pan-Pan Feng
School of Pharmaceutical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian, 271000, PR China
2 shared publicationsXiao-Shan Hao
School of Pharmaceutical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian, 271000, PR China
2 shared publicationsChong Niu
School of Pharmacy (Institute of Pharmaceutical Research), Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China
1 shared publicationFeng-Ze Wang
School of Life Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian, 271000, PR China
1 shared publicationGang-Ping Hao
School of Life Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian, People’s Republic of China
1 shared publication
Latest Publications
- 29 August 2025
- Published by Springer Nature in Cell Biochemistry and Biophysics
- Vol. 83 (4) , 5307-5319
6-Methoxydihydrosanguinarine Suppresses the Proliferation of Non-small Cell Lung Cancer Cells through Elevation of ROS and Activation of IRE1/JNK Signaling
- 29 August 2025
- Published by Springer Nature in Cell Biochemistry and Biophysics
- Vol. 83 (4) , 5307-5319
6-Methoxydihydrosanguinarine Suppresses the Proliferation of Non-small Cell Lung Cancer Cells through Elevation of ROS and Activation of IRE1/JNK Signaling
- 16 April 2023
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 378, 110487
Scutebarbatine A induces ROS-mediated DNA damage and apoptosis in breast cancer cells by modulating MAPK and EGFR/Akt signaling pathway
- 16 April 2023
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 378, 110487
Scutebarbatine A induces ROS-mediated DNA damage and apoptosis in breast cancer cells by modulating MAPK and EGFR/Akt signaling pathway
- 7 August 2022
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 365, 110076
Licochalcone B induces DNA damage, cell cycle arrest, apoptosis, and enhances TRAIL sensitivity in hepatocellular carcinoma cells
- 7 August 2022
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 365, 110076
Licochalcone B induces DNA damage, cell cycle arrest, apoptosis, and enhances TRAIL sensitivity in hepatocellular carcinoma cells
- 29 January 2021
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 35 (5) , e22731
Scutebarbatine A induces cytotoxicity in hepatocellular carcinoma via activation of the MAPK and ER stress signaling pathways
Scutebarbatine A (SBT‐A), a diterpenoid alkaloid found in the root ofScutellaria barbataD. Don, has been reported to induce the apoptosis of A549 cells. In this study, we investigated the antitumor activity of SBT‐A in human hepatocellular carcinoma (HCC) cells and the potential underlying mechanisms. Our results showed that SBT‐A inhibited the growth of HCC cells in a dose‐dependent manner. SBT‐A treatment caused cell cycle arrest and decreased the expression of cyclin B1, cyclin D1, p‐Cdc2, and p‐Cdc25C. SBT‐A triggered cell apoptosis via a caspase‐dependent pathway, and cell viability was partially restored by pretreatment with the pan‐caspase inhibitor Z‐VAD‐FMK. In HCC cells, treatment with SBT‐A increased the phosphorylation of extracellular signal‐regulated kinase 1 and 2 (ERK1/2), c‐Jun N‐terminal kinase 1 and 2 (JNK1/2), and p38 mitogen‐activated protein kinase (p38 MAPK). Moreover, SBT‐A activated endoplasmic reticulum (ER) stress through the upregulation of protein kinase RNA‐like ER kinase (PERK), activating transcription factor 4 (ATF‐4), and CCAAT‐enhancer‐binding protein (C/EBP) homologous protein (CHOP). Our data indicate that SBT‐A inhibits the proliferation of HCC cells and triggers their apoptosis via the activation of MAPK and ER stress. SBT‐A is a potential agent for the treatment of HCC.
- 29 January 2021
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 35 (5) , e22731
Scutebarbatine A induces cytotoxicity in hepatocellular carcinoma via activation of the MAPK and ER stress signaling pathways
Scutebarbatine A (SBT‐A), a diterpenoid alkaloid found in the root ofScutellaria barbataD. Don, has been reported to induce the apoptosis of A549 cells. In this study, we investigated the antitumor activity of SBT‐A in human hepatocellular carcinoma (HCC) cells and the potential underlying mechanisms. Our results showed that SBT‐A inhibited the growth of HCC cells in a dose‐dependent manner. SBT‐A treatment caused cell cycle arrest and decreased the expression of cyclin B1, cyclin D1, p‐Cdc2, and p‐Cdc25C. SBT‐A triggered cell apoptosis via a caspase‐dependent pathway, and cell viability was partially restored by pretreatment with the pan‐caspase inhibitor Z‐VAD‐FMK. In HCC cells, treatment with SBT‐A increased the phosphorylation of extracellular signal‐regulated kinase 1 and 2 (ERK1/2), c‐Jun N‐terminal kinase 1 and 2 (JNK1/2), and p38 mitogen‐activated protein kinase (p38 MAPK). Moreover, SBT‐A activated endoplasmic reticulum (ER) stress through the upregulation of protein kinase RNA‐like ER kinase (PERK), activating transcription factor 4 (ATF‐4), and CCAAT‐enhancer‐binding protein (C/EBP) homologous protein (CHOP). Our data indicate that SBT‐A inhibits the proliferation of HCC cells and triggers their apoptosis via the activation of MAPK and ER stress. SBT‐A is a potential agent for the treatment of HCC.
- Open Access
- 21 March 2020
- Published by Wiley in Journal of Cell Communication and Signaling
- Vol. 14 (4) , 377-387
CUDC-907 enhances TRAIL-induced apoptosis through upregulation of DR5 in breast cancer cells
CUDC-907 is a novel dual-acting inhibitor of phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC). In this study, we aimed to explore the anticancer effects of CUDC-907 on human breast cancer cells. Our results showed that CUDC-907 effectively inhibited breast cancer cell proliferation. Flow cytometry analysis revealed that CUDC-907 induced cell cycle arrest and apoptosis in breast cancer cells. The combined treatment of CUDC-907 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resulted in a marked increase in apoptosis and cleavage of caspase-8, −9 and poly (ADP-ribose) polymerase (PARP) in breast cancer cells. CUDC-907 enhanced expressions of death receptor 5 (DR5), reduced the levels of anti-apoptotic molecules XIAP, Bcl-2 and Bcl-xL. Knockdown of DR5 abrogated apoptosis induced by the combination of CUDC-907 and TRAIL in breast cancer cells. CUDC-907 increased the phosphorylation of JNK and p38 MAPK. JNK inhibitor pretreatment attenuated CUDC-907-induced upregulation of DR5. In summary, CUDC-907 shows potent cytotoxicity against breast cancer cells and facilitates TRAIL-mediated apoptosis through DR5 upregulation. The combination of CUDC-907 and TRAIL may be a promising therapeutic approach in the treatment of breast cancer.
- 21 March 2020
- Published by Wiley in Journal of Cell Communication and Signaling
- Vol. 14 (4) , 377-387
Open AccessCUDC-907 enhances TRAIL-induced apoptosis through upregulation of DR5 in breast cancer cells
CUDC-907 is a novel dual-acting inhibitor of phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC). In this study, we aimed to explore the anticancer effects of CUDC-907 on human breast cancer cells. Our results showed that CUDC-907 effectively inhibited breast cancer cell proliferation. Flow cytometry analysis revealed that CUDC-907 induced cell cycle arrest and apoptosis in breast cancer cells. The combined treatment of CUDC-907 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resulted in a marked increase in apoptosis and cleavage of caspase-8, −9 and poly (ADP-ribose) polymerase (PARP) in breast cancer cells. CUDC-907 enhanced expressions of death receptor 5 (DR5), reduced the levels of anti-apoptotic molecules XIAP, Bcl-2 and Bcl-xL. Knockdown of DR5 abrogated apoptosis induced by the combination of CUDC-907 and TRAIL in breast cancer cells. CUDC-907 increased the phosphorylation of JNK and p38 MAPK. JNK inhibitor pretreatment attenuated CUDC-907-induced upregulation of DR5. In summary, CUDC-907 shows potent cytotoxicity against breast cancer cells and facilitates TRAIL-mediated apoptosis through DR5 upregulation. The combination of CUDC-907 and TRAIL may be a promising therapeutic approach in the treatment of breast cancer.